½Ú¶µ¼ø ̧ÎØ¡¡¤Ï¤ë¤«
¹Ö»Õ ÀÄÌÚ¡¡¾¡É§
µÒ°÷¶µ¼ø Ä«ÁÒ¡¡Àµ
ˬÌ並µæ°÷

µÈÀî¡¡±Ñ¼ù
´ßËÜ¡¡½¼¹°
°¤Éô¡¡ÃÒ¹Ô
½ïÊý¡¡ÎÉ»ê
¾®Åç¡¡ÄçÃË

¸¦µæµ»½Ñ°÷

¾®»³¡¡Í³µ¯
ÃÓÆâ¡¡¿·»Ê

¹ÖºÂ¡Ê¸¦µæ¼¼¡Ë¤Î³µÍ×
¡¡ËÜ»ÜÀߤÎÁ°¿È¤Ç¤¢¤ë¶¦Æ±ÍøÍѸ¦µæÉô¥¢¥¤¥½¥È¡¼¥×¸¦µæ¼¼¤Ï¡¢Âç³ØÁÏΩ£±£°£°Ç¯¤òµ­Ç°¤·¤ÆµìÂç³Ø£²¹æ´Û£²¡¦£³³¬¤ËÀßÃÖ¤µ¤ì¡¢¾¼Ï£µ£¶Ç¯£±£±·î£µÆü¤è¤êÍøÍѤ¬³«»Ï¤µ¤ì¤¿¡£Ê¿À®£±£´Ç¯¤Ë¤Ïµì»ÜÀߤòÇѻߤ·¡¢£µ·î£µÆü¤ËÂç³Ø£±¹æ´Û£²³¬¤Ø°Üž¤·¤¿¡£¿·»ÜÀߤϾ²ÌÌÀѤ¬Ìó£µ£°£°Ê¿ÊƤ¢¤ê¡¢É¸¶ÂΤä°äÅÁ»ÒÁÈ´¹¤¨À¸Êª¤ò°·¤¦¤¿¤á¤Î£Ð£±¡¢£Ð£²¡¢£Ð£³¼Â¸³¼¼¤äưʪ¼Â¸³¼¼¡Ê¼Â¸³¼¼P1A¡Ë¡¦»ô°é¼¼¡ÊP1A¡Ë¡¢°Å¼¼Åù¤¬È÷¤¨¤é¤ì¡¢µ¡´ï¤È¤·¤Æ±ÕÂÎ¥·¥ó¥Á¥ì¡¼¥·¥ç¥ó¥«¥¦¥ó¥¿¡¢¥¬¥ó¥Þ¥«¥¦¥ó¥¿¡¢¥Ð¥¤¥ª¥¤¥á¡¼¥¸¥¢¥Ê¥é¥¤¥¶¡¢Ê¬¸÷¡¦·Ö¸÷¸÷Åٷס¢¥Ê¥Î¥É¥í¥Ã¥×Åù¤Î¬Äê´ï¤Î¾¤Ë£Ð£Ã£Ò´Ø·¸µ¡´ï°ì¼°¡¢¥²¥ë»£±ÆÁõÃÖ¡¢¼«Æ°¸½Áüµ¡¡¢Ä¶±ó¿´µ¡¡¢£Ã£Ï£²¥¤¥ó¥­¥å¥Ù¡¼¥¿¡¼¡¢¥Þ¥¤¥¯¥í¥×¥ì¡¼¥È¥ê¡¼¥À¡¼¡ÊRI¡¢µÛ¸÷¡¢·Ö¸÷¡¢È¯¸÷¡ËÅù¤¬ÍÑ°Õ¤µ¤ì¤Æ¤¤¤ë¡£¤³¤ì¤é¤ÎÀßÈ÷¡¦µ¡´ï¤Ï¡¢Êü¼ÍÀþ´ÉÍý¶è°è¤Ø¤ÎΩ¤ÁÆþ¤ê¾ò·ï¤òËþ¤¿¤·¤Æ¤¤¤ì¤Ð¡¢Êü¼ÍÀ­Æ±°Ì¸µÁǤòÍѤ¤¤Ê¤¤¼Â¸³¤Ç¤Î»ÈÍѤâ²Äǽ¤Ç¤¢¤ê¡¢»á̾¾Ï¤òÍѤ¤¤¿ÆþÂ༼´ÉÍý¥·¥¹¥Æ¥à¤Ë¤è¤êÌë´Ö¡¦µÙÆü¤âÍøÍѤǤ­¤ë¤è¤¦¤Ë¤Ê¤Ã¤Æ¤¤¤ë¡£
°å³Ø²Ê¶µ°é¤Ë¤Ä¤¤¤Æ
¡¡¸¦µæ¼¼ÇÛ°¤äÁªÂò¼Â½¬¤Ç¤Ï¡¢Êü¼ÍÀþ¤ËÂÑÀ­¤Î¤¢¤ëÀ¸Êª¥¯¥Þ¥à¥·¤òÍѤ¤¤Æ¡¢ÂÑÀ­µ¡¹½¤Î²òÀϤä18S-rDNA±ö´ðÇÛÎ󤪤è¤Ó·ÁÂ֤ˤè¤ëƱÄê¤ò¹Ô¤¤¡¢¾®Æ°Êª¤ÎºÎ¼è¤È´Ñ»¡¤«¤éʬ»ÒÀ¸Êª³ØŪ²òÀϤޤÇÂ賤·¤Æ¤â¤é¤Ã¤Æ¤¤¤ë¡£¤Þ¤¿¡¢¤¬¤ó¤ÎÌôºÞÂÑÀ­³ÍÆÀµ¡½ø¤Î²òÀϤÈÂÑÀ­¹îÉþÌô¤Î³«È¯¤ª¤è¤Ó¥É¥é¥Ã¥°¥Ç¥ê¥Ð¥ê¡¼¥·¥¹¥Æ¥à¤Î³«È¯¡¢ÂÑÀ­³ÍÆÀ¤Ëȼ¤¦¾åÈé´ÖÍÕž´¹µ¡½ø¤Î²òÀϤò¹Ô¤¤¡¢Î×¾²±þÍѤ˷ë¤Ó¤Ä¤¯ÆâÍƤò¼Â»Ü¤·¤Æ¤¤¤ë¡£
Âç³Ø±¡¶µ°é¡¦¸¦µæ¤Ë¤Ä¤¤¤Æ
¡¡¥¢¥¤¥½¥È¡¼¥×¤Ë´Ø¤¹¤ë¶¦ÄÌ¥«¥ê¥­¥å¥é¥à¤Ë¤ª¤¤¤Æ¹ÖµÁ¤È¼Â½¬¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£Êü¼ÍÀ­Æ±°Ì¸µÁǤÎÍøÍÑ¡¢°ÂÁ´¼è°·¤¤¤È¬ÄêË¡Åù¤Î´ðÁõ»½Ñ¤ò½¬ÆÀ¤·¡¢¤µ¤é¤ËÊü¼ÍÀ­Æ±°Ì¸µÁǤòÍѤ¤¤¿±þÍѼ½¬¤È¤·¤ÆºÙ˦Áý¿£Ç½¤Î¬Äê¤ò¹Ô¤¤¡¢Êü¼ÍÀ­Æ±°Ì¸µÁǤòÍѤ¤¤¿Ê¬ÀÏË¡¤Î´ðÁäò³Ø¤Ö¡£¤Þ¤¿¡¢Âç³Ø±¡¤Ë¤ª¤¤¤ÆÊü¼ÍÀ­Æ±°Ì¸µÁǤòÍѤ¤¤¿¸¦µæ¤ò¹Ô¤¦¾ì¹ç¤Ë¡¢»ØƳ¤ä¥¢¥É¥Ð¥¤¥¹¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£
¹ÖºÂ(¸¦µæ¼¼)¤«¤é¤Î¥á¥Ã¥»¡¼¥¸
¡¡ Åö»ÜÀߤϡ¢Ëܳؤˤª¤±¤ëÊü¼ÍÀ­Æ±°Ì¸µÁǤòÍѤ¤¤¿´ðÁðå³Ø¡¦À¸²½³Ø¸¦µæ¤Î¼Â»Ü¤È»Ù±ç¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£3H¤ä14C²½¹çʪ¤ò¤Ï¤¸¤á¡¢125I¡¢35SÅù¤Ë¤è¤ë¥¿¥ó¥Ñ¥¯¼Á¤ä²½¹çʪ¤Îɸ¼±¤È¸¡½Ð¤«¤é¡¢¤¬¤ó¤Î¸¦µæ¤äºÆÀ¸°åÎÅ¡¢¤µ¤é¤Ë¤Ï´Ä¶­Êü¼Íǽ¤äÆüÍÑÉʤ˴ޤޤì¤ëÊü¼Íǽ¤Î²òÀÏÅù¡¢Éý¹­¤¤Ãμ±¤Èµ»½Ñ¤ÎÃßÀѤ¬¤¢¤ê¡¢¤³¤ì¤é¤òɬÍפȤ¹¤ë¶µ°÷¡¦¸¦µæ¼Ô¡¦³ØÀ¸¤ËÌç¸Í¤ò³«¤¤¤Æ¤¤¤ë¡£ÁÈ´¹¤¨£Ä£Î£Á¼Â¸³¼¼¤òÈ÷¤¨¤Æ¤¤¤ë¤³¤È¤«¤é¡¢É¸¶ÂΤäÁÈ´¹¤¨£Ä£Î£ÁÀ¸Êª¤òÍѤ¤¤¿¼Â¸³¤â¼õ¤±Æþ¤ì¤Æ¤¤¤ë¤Î¤Ç¡¢¤¼¤Ò¿¤¯¤Î¿Í¤ËÍøÍѤ·¤Æ¤¤¤¿¤À¤­¤¿¤¤¡£
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¶µ°éôÅö
¹ÖµÁ²ÊÌÜ̾¾Î¤ÈÂоݳØǯ

ʬ»Ò¤«¤éÀ¸Ì¿¤Ø¡¡¹ÖµÁ¡¡£²Ç¯¡ÊÀÄÌÚ¡Ë
¥Ò¥È¤Î»þ´ÖÀ¸Êª³Ø¡¡¹ÖµÁ¡¡£³Ç¯¡ÊÀÄÌÚ¡Ë
Ìȱ֤ÈÀ¸ÂÎËɸ桡¹ÖµÁ¡¡£³Ç¯¡ÊÀÄÌÚ¡Ë
°å³Ø±Ñ¸ìÀìÌçʸ¸¥¾¶ÆÉ¡¡ £³Ç¯¡Ȩ̂ÎØ¡¢ÀÄÌÚ¡Ë

¼Â½¬²ÊÌÜ̾¾Î¤ÈÂоݳØǯ

ʬ»Ò¤«¤éÀ¸Ì¿¤Ø±é½¬¡¡2ǯ¡Ȩ̂ÎØ¡¢ÀÄÌÚ¡Ë
ʬ»Ò¤«¤éÀ¸Ì¿¤Ø¼Â½¬¡¡2ǯ¡Ȩ̂ÎØ¡¢ÀÄÌÚ¡Ë
Ìȱֳؼ½¬¡¡3ǯ¡ÊÀÄÌÚ¡Ë
¾É¸õÉÂÂֱ齬­¶¡¡3ǯ¡Ȩ̂ÎØ¡¢ÀÄÌÚ¡Ë
¸¦µæ¼¼ÇÛ°¡¡3ǯ¡Ȩ̂ÎØ¡¢ÀÄÌÚ¡Ë

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
Âç³Ø±¡Ã´Åö²ÊÌÜ̾¾Î
Âç³Ø±¡¥¬¥¤¥É¼ø¶ÈºÙÌÜ¡¡¡¡¥¢¥¤¥½¥È¡¼¥×¼Â¸³¸¦µæ»ÜÀß¡Ê93¥Ú¡¼¥¸¡Ë¤ò¤´»²¾È¤¯¤À¤µ¤¤
¡¦Âç³Ø±¡¶¦ÄÌ¥«¥ê¥­¥å¥é¥à¡¡¥¢¥¤¥½¥È¡¼¥×I¡Ȩ̂ÎØ¡¢ÀÄÌÚ¡Ë
¡¦Âç³Ø±¡¶¦ÄÌ¥«¥ê¥­¥å¥é¥à¡¡¥¢¥¤¥½¥È¡¼¥×II¡Ȩ̂ÎØ¡¢ÀÄÌÚ¡Ë
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¸¦µæ¥Æ¡¼¥Þ
¼Â¸³¸¦µæ

  1. ´Ä¶­Êü¼Íǽ
    Ê¡ÅçÂè°ì¸¶»ÒÎÏȯÅŽê»ö¸ÎͳÍè¤ÎÊü¼ÍÀ­Êª¼Á¤ÎÄ´ºº¡¦¸¦µæ
    ´Ä¶­Ãæ¤ÎÊü¼ÍÀ­¥¹¥È¥í¥ó¥Á¥¦¥àʬÀÏË¡¤Î³«È¯
    ¥é¥¸¥¦¥à¡¦¥é¥É¥ó²¹Àô¤ÎÊü¼Íǽ¤Ë´Ø¤¹¤ë¸¦µæ
  2. Êü¼ÍÀþÀ¸Êª³Ø
    ¥¯¥Þ¥à¥·¤ÎÊü¼ÍÀþÂÑÀ­µ¡¹½¤Î²òÀÏ
  3. ¤¬¤ó¤ÎÀ¸²½³ØŪ¸¦µæ
    ¹³¤¬¤óºÞÂÑÀ­³ÍÆÀµ¡½ø¤Î²òÀϤÈÂÑÀ­¹îÉþÌô¤Î³«È¯
    ¤¬¤óºÙ˦¤ÎÀȼåÀ­¤Ë´Ø¤¹¤ë¸¦µæ
    ¥ß¥»¥ë¤òÍѤ¤¤¿¥É¥é¥Ã¥°¥Ç¥ê¥Ð¥ê¡¼¥·¥¹¥Æ¥à¤Î³«È¯
    ¥×¥í¥Æ¥¢¥½¡¼¥àÁ˳²ºÞÂÑÀ­³ÍÆÀ¤Ëȼ¤¦¾åÈé´ÖÍÕž´¹µ¡½ø¤Î²òÀÏ
    ÌôºÞÂÑÀ­¤¬¤óºÙ˦¤ËÂФ¹¤ë¥¯¥ë¥¯¥ß¥ó¤Ë¤è¤ë²½³ØÎÅË¡
    ¸Æµ¤¼ðáç¥Þ¡¼¥«¡¼¤Î²òÀϤȤ¬¤ó¤ÎÁá´üȯ¸«Ë¡¤Î³«È¯

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¶ÈÀÓ
  1. Kawamura A, Yoshida S, Aoki K, Shimoyama Y, Yamada K, Yoshida K. DYRK2 maintains genome stability via neddylation of cullins in response to DNA damage. J Cell Sci. 2022 Jun 1;135(11):jcs259514. doi: 10.1242/jcs.259514.
  2. Abe T, Horisawa Y, Kikuchi O, Ozawa-Umeta H, Kishimoto A, Katsuura Y, Imaizumi A, Hashimoto T, Shirakawa K, Takaori-Kondo A, Yusa K, Asakura T, Kakeya H, Kanai M. Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin. Eur J Pharmacol. 2022 Nov 15;935:175321.
  3. Yamada K, Oikawa T, Kizawa R, Motohashi S, Yoshida S, Kumamoto T, Saeki C, Nakagawa C, Shimoyama Y, Aoki K, Tachibana T, Saruta M, Ono M, Yoshida K. Unconventional Secretion of PKC¦Ä Exerts Tumorigenic Function via Stimulation of ERK1/2 Signaling in Liver Cancer. Cancer Res. 2021 Jan 15;81(2):414-425.
  4. Yoshida S, Aoki K, Fujiwara K, Nakakura T, Kawamura A, Yamada K, Ono M, Yogosawa S, Yoshida K. The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis. Elife. 2020 Aug 6;9:e57381.
  5. Kumamoto T, Yamada K, Yoshida S, Aoki K, Hirooka S, Eto K, Yanaga K, Yoshida K. Impairment of DYRK2 by DNMT1-mediated transcription augments carcinogenesis in human colorectal cancer. Int J Oncol. 2020 Jun;56(6):1529-1539.
  6. Asakura T, Yokoyama M, Shiraishi K, Aoki K, Ohkawa K. Chemotherapeutic Effect of CD147 Antibody-labeled Micelles Encapsulating Doxorubicin Conjugate Targeting CD147-Expressing Carcinoma Cells. Anticancer Res. 2018 Mar;38(3):1311-1316.
  7. Okabe H, Aoki K, Yogosawa S, Saito M, Marumo K, Yoshida K. Downregulation of CD24 suppresses bone metastasis of lung cancer. Cancer Sci. 2018 Jan;109(1):112-120.
  8. Yamamoto T, Taira Nihira N, Yogosawa S, Aoki K, Takeda H, Sawasaki T, Yoshida K. Interaction between RNF8 and DYRK2 is required for the recruitment of DNA repair molecules to DNA double-strand breaks. FEBS Lett. 2017 Mar;591(6):842-853.
  9. ̧ÎؤϤ뤫, ½ïÊýÎÉ»ê, ²ÃÆ£·ë²Ö, ¾®ÅçÄçÃË¡§¥±¥¤»À¥Ð¥ê¥¦¥à¤ò¼çÀ®Ê¬¤È¤¹¤ëµÛÃåºÞ¤Ø¤Î³¤¿å¡¦Î¦¿å¤Ë¤ª¤±¤ë Sr ¤ÎµÛÃåÆÃÀ­, Âè21²ó´Ä¶­Êü¼Íǽ¸¦µæ²ñ Proceedings, KEK Proceedings 2020(4) 176-179
  10. Minowa H. Image analysis of radiocesium distribution in coniferous trees two years after the Fukushima Daiichi Nuclear Power Plant accident. J Radioanal Nucl Chem 2015; 303: 1601-5
¼ç¤Ê¶¥ÁèŪ¸¦µæÈñ
  • ̧ÎؤϤ뤫¡ÊÂåɽ¡Ë¡Ö¿åÃæ¤ÎÊü¼ÍÀ­¥¹¥È¥í¥ó¥Á¥¦¥à¤Î°ÂÁ´¡¢¿×®¡¢°Â²Á¤ÊʬÀÏË¡¤Î³«È¯¡×
    ¸¶»ÒÎϵ¬À©Ä£ ÎáÏ£³Ç¯ÅÙÊü¼ÍÀþ°ÂÁ´µ¬À©¸¦µæÀïάŪ¿ä¿Ê»ö¶ÈÈñ. 2021ǯ

  • ̧ÎؤϤ뤫¡Êʬô¡Ë¡Ö¡ÖÆü¾ï¤Î²Ê³Ø¥³¥ß¥å¥Ë¥±¡¼¥·¥ç¥ó¡×¤¬ÊѲ½¤¹¤ë¶ÉÌ̤ο³ÑŪʬÀÏ¡×
    ÆüËܳؽѿ¶¶½²ñ ²Ê³Ø¸¦µæÈñ½õÀ®»ö¶È ´ðÈ׸¦µæ(C) 2019ǯ- 2023ǯ
¤½¤Î¾

°ìÈ̼ÒÃÄË¡¿Í¡¡ÆüËÜÊü¼Í²½³Ø²ñ¡¡´Æ»ö¡Ȩ̂ÎØ¡Ë

NPOË¡¿Í¡¡Êü¼ÍÀþ¶µ°é¥Õ¥©¡¼¥é¥à¡¡Íý»ö¡ÊÄ«ÁÒ¡Ë

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø